Menu
Back to User profile » Prof. Dr. Paolo Bonfanti
Papers published by Prof. Dr. Paolo Bonfanti:
HIV and SARS-CoV-2 Co-Infection: What are the Risks?
Squillace N, Ricci E, Colella E, Bonfanti P
Infection and Drug Resistance 2021, 14:3991-4014
Published Date: 28 September 2021
The Role for Tocilizumab in COVID-19 Patients: Reflections on Monza Cohort Data
Capici S, Sala L, Galimberti S, Valsecchi MG, Squillace N, Gustinetti G, Cazzaniga ME, Bonfanti P
Infection and Drug Resistance 2021, 14:1389-1392
Published Date: 13 April 2021
The Effect of Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) on Liver Enzymes, Glucose, and Lipid Profile
Squillace N, Ricci E, Menzaghi B, De Socio GV, Passerini S, Martinelli C, Mameli MS, Maggi P, Falasca K, Cordier L, Celesia BM, Salomoni E, Di Biagio A, Pellicanò GF, Bonfanti P
Drug Design, Development and Therapy 2020, 14:5515-5520
Published Date: 15 December 2020
Bone Safety of Dolutegravir-Containing Regimens in People Living with HIV: Results from a Real-World Cohort
Bonfanti P, De Vito A, Ricci E, Menzaghi B, Orofino G, Squillace N, Molteni C, De Socio GV, Salomoni E, Celesia BM, Dentone C, Colombo V, Madeddu G
Infection and Drug Resistance 2020, 13:2291-2300
Published Date: 14 July 2020
Cost of human immunodeficiency virus infection in Italy, 2007–2009: effective and expensive, are the new drugs worthwhile?
Rizzardini G, Restelli U, Bonfanti P, Porazzi E, Ricci E, Foglia E, Carenzi L, Croce D
ClinicoEconomics and Outcomes Research 2012, 4:245-252
Published Date: 5 September 2012